ARTICLE | Finance

Buysiders are all about market-creating catalysts in 2024

BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories

January 20, 2024 2:37 AM UTC

As buysiders anticipate a biotech market recovery in 2024, they’re looking to catalysts that can create, or greatly expand, new commercial markets to help pull the industry out of its two-and-a-half year slump. 

Recovery isn’t just about the milestones. Plenty of positive, even transformational clinical readouts have been reported over the past few years that failed to boost the sector, and in some cases even the relevant company. ...